bluebird bio, Inc. (BLUE): Price and Financial Metrics


bluebird bio, Inc. (BLUE): $18.44

-0.22 (-1.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLUE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

BLUE POWR Grades


  • Value is the dimension where BLUE ranks best; there it ranks ahead of 55.99% of US stocks.
  • The strongest trend for BLUE is in Momentum, which has been heading down over the past 48 weeks.
  • BLUE ranks lowest in Stability; there it ranks in the 8th percentile.

BLUE Stock Summary

  • BLUE's price/sales ratio is 25.1; that's higher than the P/S ratio of 91.71% of US stocks.
  • Revenue growth over the past 12 months for bluebird bio Inc comes in at -79.03%, a number that bests merely 2.05% of the US stocks we're tracking.
  • In terms of volatility of its share price, BLUE is more volatile than 90.31% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to bluebird bio Inc are CYCN, APTX, BCDA, OTIC, and CLSD.
  • Visit BLUE's SEC page to see the company's official filings. To visit the company's web site, go to www.bluebirdbio.com.

BLUE Valuation Summary

  • In comparison to the median Healthcare stock, BLUE's price/sales ratio is 547.37% higher, now standing at 24.6.
  • BLUE's price/sales ratio has moved down 401.2 over the prior 100 months.
  • Over the past 100 months, BLUE's price/earnings ratio has gone up 14.9.

Below are key valuation metrics over time for BLUE.

Stock Date P/S P/B P/E EV/EBIT
BLUE 2021-08-31 24.6 1.3 -1.5 -1.3
BLUE 2021-08-30 24.0 1.2 -1.4 -1.2
BLUE 2021-08-27 24.4 1.2 -1.5 -1.3
BLUE 2021-08-26 24.1 1.2 -1.4 -1.2
BLUE 2021-08-25 24.5 1.2 -1.5 -1.3
BLUE 2021-08-24 24.0 1.2 -1.4 -1.2

BLUE Growth Metrics

  • The 2 year net cashflow from operations growth rate now stands at -96.25%.
  • Its year over year revenue growth rate is now at 346.98%.
  • Its 5 year revenue growth rate is now at 184.65%.
BLUE's revenue has moved up $10,743,000 over the prior 33 months.

The table below shows BLUE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 50.247 -652.948 -842.129
2021-03-31 241.665 -467.557 -621.892
2020-12-31 250.734 -470.351 -618.695
2020-09-30 250.023 -474.134 -642.168
2020-06-30 239.66 -438.735 -653.456
2020-03-31 54.066 -616.351 -827.773

BLUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BLUE has a Quality Grade of D, ranking ahead of 17.93% of graded US stocks.
  • BLUE's asset turnover comes in at 0.029 -- ranking 356th of 677 Pharmaceutical Products stocks.
  • NERV, GNCA, and OTLC are the stocks whose asset turnover ratios are most correlated with BLUE.

The table below shows BLUE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 0.594 -0.648
2021-03-31 0.129 0.972 -0.495
2020-12-31 0.136 0.978 -0.496
2020-09-30 0.137 0.980 -0.528
2020-06-30 0.132 0.981 -0.546
2020-03-31 0.030 0.934 -0.590

BLUE Price Target

For more insight on analysts targets of BLUE, see our BLUE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $82.33 Average Broker Recommendation 1.46 (Moderate Buy)

BLUE Stock Price Chart Interactive Chart >

Price chart for BLUE

BLUE Price/Volume Stats

Current price $18.44 52-week high $59.32
Prev. close $18.66 52-week low $17.14
Day low $18.30 Volume 642,600
Day high $18.71 Avg. volume 1,635,668
50-day MA $20.69 Dividend yield N/A
200-day MA $31.46 Market Cap 1.25B

bluebird bio, Inc. (BLUE) Company Bio


Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.


BLUE Latest News Stream


Event/Time News Detail
Loading, please wait...

BLUE Latest Social Stream


Loading social stream, please wait...

View Full BLUE Social Stream

Latest BLUE News From Around the Web

Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

Bluebird Bio Files US Application For β-thalassemia Gene Therapy

Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy. The application covers adult, adolescent, and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions across all genotypes. Read Next: Bluebird Bio's Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold. The FDA previously granted beti-cel Orphan Drug status and

Yahoo | September 22, 2021

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With -thalassemia Who Require Regular Red Blood Cell Transfusions

bluebird bio, Inc. (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food

Business Wire | September 21, 2021

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

CAMBRIDGE, Mass., September 21, 2021--bluebird bio, Inc. (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designati

Yahoo | September 21, 2021

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.

Chris Markoch on InvestorPlace | September 15, 2021

2seventy bio Announces Upcoming Investor Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventys Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy September 21, 2021, 11:00am-12:00pm ET Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy September 22, 2021, 1:00-2:00pm ET To access the

Business Wire | September 13, 2021

Read More 'BLUE' Stories Here

BLUE Price Returns

1-mo 2.84%
3-mo -40.34%
6-mo -40.40%
1-year -67.67%
3-year -86.76%
5-year -74.13%
YTD -57.38%
2020 -50.69%
2019 -11.54%
2018 -44.30%
2017 188.65%
2016 -3.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 2.4079 seconds.